key: cord-0961912-3lytepzw authors: Landsberg, Hannah E.; Turcinovic, Jackie; Sullivan, Madison; Connor, John H.; Hamer, Davidson H.; Platt, Judy T. title: Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster date: 2021-10-30 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.10.053 sha: fdb74f66055366f25a093e4da3e3a3558c6bcd57 doc_id: 961912 cord_uid: 3lytepzw The SARS-CoV-2 sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the United States, has been responsible for significant morbidity and mortality. In May 2021, Delta was escalated to a variant of concern by international authorities. We report a cluster of SARS-CoV-2 Delta cases detected in Boston, Massachusetts, in May 2021 involving a recent traveler from India and subsequent transmission to two of three close contacts. All three close contacts experienced the same primary exposure events but differed in vaccination status. The two close contacts that eventually tested positive were unvaccinated. The other had received one dose of the BNT162b (Pfizer-BioNTech) vaccine prior to exposure and received their second dose two days after exposure. This case series illustrates the effectiveness of partial vaccination in blocking Delta transmission to the vaccinated individual under circumstances where the transmission probability is high for unvaccinated individuals. Variant of concern PCR testing Contact Tracing With the world in a race to vaccinate as many people as possible, concerns about vaccine efficacy have continued to arise particularly related to variants of concern (VoC). The latest variant to be upgraded to a VoC was first discovered in India: B.1.617. This variant has three different subtypes including Delta or B.1.617.2, which has become the most reported lineage in India and has been responsible for a devastating second wave of infection in the country (Outbreak.info, 2021) . This variant is defined by seven mutations in the spike protein, two of which, L452R and T478K, are suspected to increase transmissibility (Adams, 2021). During recent months, Delta has rapidly spread in the United Kingdom through travel-associated introductions and community transmission (Public Health England, 2021), and case numbers are increasing in the United States (CDC, 2021). Massachusetts has reported 185 total Delta cases as of July 1, 2021, with the most recent case reported on June 14, 2021 (Outbreak.info, 2021). There have been concerns about vaccine efficacy against Delta. Recent studies have shown that antibodies from individuals vaccinated with BNT162b had reduced binding to Delta (Bernal et al, 2021) . Despite potentially reduced effectiveness in individuals, the BNT162b vaccine is still protective at the populational level (Bernal et al, 2021) . However, these studies do not investigate protection of vaccinated individuals compared to unvaccinated individuals in the same exposure event. The transmission cluster described here addresses this gap in understanding. Anterior nares swabs were self-collected into sterile saline at Boston University (BU) testing sites (Hamer et al, 2021 ). The BU Testing Laboratory reverse transcriptase polymerase chain reaction (RT-PCR) was used for initial diagnosis of COVID-19. Total RNA was extracted from leftover saline, and SARS-CoV-2 genomic RNA was sequenced using amplification with the ARTIC v3 primer set. Raw sequences were aligned to the Wuhan-Hu-1 reference genome (GenBank accession nos. MN908947.3). Genome coverage was assessed with SAMtools, and SNVs were called with LoFreq. Consensus sequences were assembled from SNV tables and the Wuhan-Hu-1 reference for nucleotides with > 10 aligned reads. Pangolin was used for lineage assignment following consensus sequence assembly. A nasopharyngeal swab collected at a local Boston hospital was also analyzed by RT-PCR. Case investigation and contact tracing conducted by BU contact tracers following adapted CDC/MDPH protocol (Hamer et al, 2021) On May 10 th , Boston University's COVID-19 management team, Healthway, received notification from Boston Public Health Commission reporting a 23-year-old BU-affiliated case who had tested positive outside of the BU surveillance network. The individual had recent travel from India and developed a cough and sore throat one day after arrival to the US. Upon case investigation and contact tracing, three individuals within the BU surveillance network were identified as close contacts and placed in close contact quarantine. Contacts with the initial case for all three individuals included two primary unmasked exposure events: a car pool drive and an indoor dining event. The four individuals were in a compact sedan vehicle with the windows closed for a total of 60 minutes. The indoor dining event lasted approximately 1 hour and 40 minutes. The restaurant is located on the first floor of a large apartment complex. At the time, Massachusetts restaurants were required to separate tables by at least six feet, unless separated by walls or plexiglass dividers, and patrons were required to sit at a table (no standing room service), and required to order food during their visit. All patrons were held to a 90minute time limit. While the group was dining, the restaurant was not crowded and the four individuals sat at the back of the restaurant, away from the closed windows and closed main door, and were at least 10 feet from the nearest customer. Two of the three BU contacts, both unvaccinated, had positive SARS-CoV-2 PCR tests 5 and 7 days after these exposure events and were placed in isolation. One remained asymptomatic and one Anterior nares swab samples from the two individuals who tested positive for SARS-CoV-2 were sequenced to determine the infectious variant using an Artic-primer based Amp-seq approach. Both samples returned highquality sequence (aligned reads: 4.4E+7 and 7.4E+6; median coverage: 1.2E+5 and 1.5E+3). Pangolin-based sequence comparison identified both genomes as Delta variant, consistent with Mass DPH reporting that the index case was also infected with a Delta variant. We report a Delta variant involving three close contacts who all had the same unmasked exposure of car pool and indoor dining to a Delta SARS-CoV-2 index case. The obvious differing factor was mRNA partialvaccination status for one close contact. This contact tested negative with PCR testing 5 separate times up to 11 days after exposure whereas all other close contacts became infected. While this case series reviews one cluster of three individuals, and vaccine response can be variable, the series does show promising evidence of vaccine protection after exposure to the Delta variant under extended close-contact conditions that were sufficient to transmit from the index case to two unvaccinated individuals. In addition to vaccine protection, the importance of early and effective contact tracing, quarantine and isolation measures remain critical in controlling transmission. The identified close contacts were placed into quarantine prior to significant virus amplification (as measured by anterior nares-based rt-PCR) and therefore blocked two potential transmission chains in the community. Partial mRNA vaccination provided enough protection to prevent infection from a significant indoor, unmasked exposure and further spread of the Delta variant. Epidemiological investigation in combination with biological investigation allowed for further analysis of the clusters impact. On a larger scale, mRNA vaccines could prove to prevent large clusters which were seen with other variants of concern, including Alpha. Vaccine outreach efforts should continue to be strengthened and the ongoing collaboration between epidemiological and biological investigations should continue. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/98638 0/Variants_of_Concern_VOC_Technical_Briefing_11_England.pdf (Access on May 30, 2021) Figure 1 . Epidemiologic timeline of events from exposure event to cluster identifcation. The main timeline includes the investigation of case interactions. The timeline to the right includes the testing timeline of close contact #3 as part of the BU surveillance network What scientists know about new, fast-spreading coronavirus variants Biorender.com, publication license & licensing rights Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease SARS-CoV-2 variant classifications and definitions Threat Assessment Brief: Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA SARS-CoV-2-B.1.617-variants-in-India-and-situation-in-the-EUEEA.pdf Assessment of a COVID-19 control plan on an urban university campus during a second wave of the pandemic SARS-CoV-2 (hCoV-19) Mutation Reports SARS-CoV-2 Variants of Concern and Variants under Investigation in England -Technical Briefing The authors have no conflicts of interest to declare. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Boston University Charles River Campus Institutional Review Board determined the case series, protocol #6131X, meets criteria for exemption in accordance with CFR 46.104(d) 4(ii).